Drinker Biddle & Reath LLP
Recent News About Drinker Biddle & Reath LLP
-
FAEGRE DRINKER BIDDLE & REATH LLP: Unfinished Business with the TCPA
Partners Laura Phillips and Mike Daly are speaking on “Unfinished Business with the TCPA” for a CLE webinar of the Federal Communications Bar Association (FCBA) on Tuesday, April 21, 2020. -
DRINKER BIDDLE & REATH LLP: Advocacy for Inclusion: A Panel Discussion with Ellery Schempp and the ACLU of Pennsylvania
In celebration of the American Civil Liberties Union of Pennsylvania’s centennial anniversary, Faegre Drinker Biddle & Reath’s Diversity & Inclusion Committee invites you to reflect on significant advocacy milestones that have challenged barriers to inclusion. -
Judge in landmark $8 billion Risperdal case cuts punitive damages award down to $6.8 million
PHILADELPHIA – After a Philadelphia jury rendered a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal in October, the judge who presided over the trial reduced the verdict to $6.8 million on Friday. -
Judge accused of high-fiving jurors after $8B Risperdal verdict refuses to step down from trial
PHILADELPHIA – A Philadelphia judge has struck down an attempt to recuse him from future proceedings surrounding a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal. -
Judge in $8 billion Risperdal trial high-fived the jury, Johnson & Johnson says
PHILADELPHIA – Johnson & Johnson, which was recently hit with a staggering $8 billion punitive damages verdict at the end of a recent trial surrounding anti-psychotic drug Risperdal in Philadelphia, has filed motions to set it aside and call for a retrial – in addition to calling for the presiding judge to recuse himself from the case moving forward, alleging improper conduct like high-fives and pictures with jurors. -
Facing 12,000 lawsuits, J&J has expert testify that there is no link between talc and ovarian cancer
TRENTON, N.J. – The fate of about 12,000 lawsuits claiming Johnson & Johnson’s talc-containing baby powder causes women to develop both ovarian cancer and mesothelioma, will be decided after eight days of expert witness testimony in a New Jersey federal court. -
Janssen win in Philly Risperdal case overturned by appeals court
HARRISBURG – The Superior Court of Pennsylvania has reinstated a Risperdal lawsuit which was thrown out after 11 days of trial proceedings in a Philadelphia court in December 2016 and said its original granting of nonsuit was improper. -
DRINKER BIDDLE: Drinker Biddle Names Dan Aiken to Lead Philadelphia Office
Drinker Biddle & Reath LLP announced that Daniel H. Aiken has been appointed Regional Partner in Charge (RPIC) of the firm’s Philadelphia office. Aiken’s appointment took effect on May 24, 2019. -
DRINKER BIDDLE: Drinker Biddle Celebrates New Partner Class Reflecting Firm’s Ongoing Commitment to Gender Equity
Drinker Biddle & Reath LLP is pleased to announce the election of nine new partners, representing four of the firm’s offices and six practices. -
DRINKER BIDDLE: Maria Lewis Recognized for Advancement and Equality in the Legal Profession
Maria L. H. Lewis, Drinker Biddle Chief Diversity Officer and Counsel, recently received two prestigious awards. -
Talc lawsuits come to Philadelphia; Plaintiffs around the country have scored massive verdicts
PHILADELPHIA – Lawsuits alleging that Johnson & Johnson’s talcum powder contained asbestos fibers that led female plaintiffs to develop cancer could be the latest legal trend with a track record of multimillion-dollar verdicts to make its way to the Philadelphia court system. -
Philly court denies Johnson & Johnson's motion for interlocutory appeal in Risperdal punitive damages case
PHILADELPHIA – A Philadelphia judge has denied a motion from counsel for pharmaceutical giant Johnson & Johnson to seek immediate appeal, in a Risperdal case where the possibility of punitive damages being applied remains in play. -
Johnson & Johnson, Bayer seek dismissal of 12 Philadelphia Xarelto lawsuits, say fact sheets are missing
PHILADELPHIA – According to a recent filing, counsel for the manufacturers of blood thinner-drug Xarelto are looking to have the lawsuits of certain plaintiffs dismissed with prejudice, supposedly for not complying with filing guidelines. -
DRINKER BIDDLE & REATH: Part 16 of “The Restricting Covenant” Series: Civil Contempt and Covenants Not to Compete
Make no bones about it, non-compete disputes can be litigious, contentious, and downright nasty. -
Airgas claims former senior VP, Carlyle stole confidential information
PHILADELPHIA — Airgas Inc. is suing The Carlyle Group and Carlyle Investment Management LLC and former Airgas senior vice president of corporate development Leslie Graff, citing alleged breach of employee duty and loyalty, aiding and abetting breach of duty and loyalty and violation of the Pennsylvania Uniform Trade Secrets Act. -
Judge won't make Hagens Berman pay for discovery as decades-old birth defects are litigated
PHILADELPHIA – A federal judge in Philadelphia recently denied an attempt on the part of pharmaceutical giant GlaxoSmithKline to reallocate costs and fees incurred through still-pending investigative discovery, to the plaintiffs’ counsel in a thalidomide products injury action. -
Third Circuit: Lawsuit blaming Disney World for copperhead bite shouldn't be heard in Pennsylvania
PHILADELPHIA – For jurisdictional reasons, a federal appeals court recently denied the appeal of a Holland Township couple who filed a negligence lawsuit against Walt Disney, for one of the plaintiffs being bitten and injured by a snake during a visit to the Walt Disney World resort in Florida. -
Payroll dispute case and related arbitration issue remanded to District Court
PHILADELPHIA – A federal appeals court has determined that a lower court erroneously threw out a motion to dismiss before properly resolving a separate motion to compel arbitration in a payroll dispute litigation. -
Former FDA commissioner says Xarelto's manufacturers didn't warn patients of drug's risks
NEW ORLEANS – In the first week of the first federal bellwether trial connected to Xarelto, the former commissioner of the Food & Drug Administration (FDA) testified to his belief that the manufacturers of Xarelto misled patients on potential risks associated with the blood-thinning medication. -
First Xarelto federal bellwether trial beginning in Louisiana court
NEW ORLEANS – The initial bellwether trial to ascertain whether the manufacturers of Xarelto are liable for claims which allege the blood-thinning medication caused injury or death to more than 15,000 patients was slated to begin Monday in a Louisiana federal court.